Clinical Trials Logo
  1. Home
  2. Astrocytoma, Grade III
  3. NCT04757662

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Astrocytoma, Grade IV Clinical Trial

Official title:
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Clinical Trial Summary

Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of treatment resistance to chemoradiotherapy. Tadalafil, an FDA-approved drug with inexpensive cost and excellent safety profile, has been shown to effectively reduce MDSCs and restore T-cell activation in the peripheral blood and in the tumor microenvironment. The purpose of this study is to investigate the impact of targeting MDSCs in newly diagnosed IDH-wildtype grade III-IV astrocytoma by combining tadalafil with standard of care radiation therapy (RT) and temozolomide (TMZ).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04757662
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase Phase 1
Start date May 14, 2021
Completion date June 7, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02766699 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) Phase 1
Not yet recruiting NCT06017063 - Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields N/A
Completed NCT02366728 - DC Migration Study for Newly-Diagnosed GBM Phase 2
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Withdrawn NCT02432417 - The Addition of Chloroquine to Chemoradiation for Glioblastoma, Phase 2
Withdrawn NCT05218408 - CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type Phase 1/Phase 2
Recruiting NCT05375318 - BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
Not yet recruiting NCT06161974 - Study of Olutasidenib and Temozolomide in HGG Phase 2
Withdrawn NCT00943462 - Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
Completed NCT02709226 - Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma Phase 1
Recruiting NCT05229198 - ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
Completed NCT01240460 - Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection Phase 1
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting NCT06157541 - T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Phase 1/Phase 2
Terminated NCT02510950 - Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT03956706 - Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas N/A
Completed NCT02465268 - Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme Phase 2
Completed NCT03072134 - Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Phase 1
Recruiting NCT03861299 - The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. N/A